After finishing at $0.10 in the prior trading day, Nutex Health Inc (NASDAQ: NUTX) closed at $0.10, up 3.28%. In other words, the price has increased by $+0.0033 from its previous closing price. On the day, 2287783 shares were traded.
Ratios:
Our goal is to gain a better understanding of NUTX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.20. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.34. In the meantime, Its Debt-to-Equity ratio is 3.64 whereas as Long-Term Debt/Eq ratio is at 3.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Northland Capital on February 22, 2023, initiated with a Outperform rating and assigned the stock a target price of $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 20 ’23 when Vo Thomas T. bought 275,200 shares for $0.23 per share. The transaction valued at 62,195 led to the insider holds 269,822,776 shares of the business.
Vo Thomas T. bought 224,800 shares of NUTX for $51,704 on Nov 17 ’23. The Chief Executive Officer now owns 269,547,576 shares after completing the transaction at $0.23 per share. On Nov 15 ’23, another insider, DeTillio Joshua, who serves as the Chief Operating Officer of the company, bought 140,000 shares for $0.24 each. As a result, the insider paid 34,174 and bolstered with 140,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUTX now has a Market Capitalization of 75.04M and an Enterprise Value of 375.94M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.33 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 1.62 whereas that against EBITDA is 83.73.
Stock Price History:
Over the past 52 weeks, NUTX has reached a high of $1.49, while it has fallen to a 52-week low of $0.10. The 50-Day Moving Average of the stock is 0.1449, while the 200-Day Moving Average is calculated to be 0.2602.
Shares Statistics:
The stock has traded on average 1.70M shares per day over the past 3-months and 1.74M shares per day over the last 10 days, according to various share statistics. A total of 650.22M shares are outstanding, with a floating share count of 435.94M. Insiders hold about 41.50% of the company’s shares, while institutions hold 4.79% stake in the company. Shares short for NUTX as of Feb 15, 2024 were 2.5M with a Short Ratio of 1.47, compared to 2.24M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.33% and a Short% of Float of 0.58%.
Earnings Estimates
Its stock is currently analyzed by 1 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.02. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.02 and -$0.02 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.01, with 1 analysts recommending between -$0.01 and -$0.01.
Revenue Estimates
1 analysts predict $71.4M in revenue for the current quarter. It ranges from a high estimate of $71.4M to a low estimate of $71.4M. As of the current estimate, Nutex Health Inc’s year-ago sales were $53.72M, an estimated increase of 32.90% from the year-ago figure.
A total of 1 analysts have provided revenue estimates for NUTX’s current fiscal year. The highest revenue estimate was $249.4M, while the lowest revenue estimate was $249.4M, resulting in an average revenue estimate of $249.4M. In the same quarter a year ago, actual revenue was $219.29M, up 13.70% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $316.2M in the next fiscal year. The high estimate is $316.2M and the low estimate is $316.2M. The average revenue growth estimate for next year is up 26.80% from the average revenue estimate for this year.
